Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 17/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20377554 | 0.88 | MAOB (0.61) | MAOBMEN1HSP90AA1KMT2AMAOA | |
| SCHEMBL16047640 | 0.88 | MEN1 (0.66) | MAOBMEN1HSP90AA1KMT2AMAOA | |
| SCHEMBL16047497 | 0.86 | MEN1 (0.58) | MAOBMEN1HSP90AA1KMT2AMAOA | |
| SCHEMBL16047063 | 0.83 | MAOB (0.81) | MAOBMAOA | |
| SCHEMBL16047028 | 0.82 | MAOB (0.60) | MAOBMAOAKDM4EHPGD | |
| SCHEMBL16047130 | 0.82 | MEN1 (0.66) | MAOBMEN1HSP90AA1KMT2AMAOA | |
| SCHEMBL1557560 | 0.81 | MAOB (0.66) | MAOBKMT2AMAOA | |
| SCHEMBL1285015 | 0.81 | TSHR (0.59) | MEN1HSP90AA1KMT2AKDM4EALDH1A1 | |
| SCHEMBL16046966 | 0.80 | MAOB (0.74) | MAOBMAOA | |
| SCHEMBL16046739 | 0.78 | MAOB (1.00) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970125-B1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2018-07-18 | — | — | EP | claimed |
| US-9956213-B2 | Substituted naphthyridine and quinoline compounds as MAO inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-05-01 | — | — | US | claimed |
| US-20160074377-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE, LLC | 2016-03-17 | — | — | US | claimed |
| EP-2970125-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | Dart Neuroscience (Cayman) Ltd (KY) | 2016-01-20 | — | — | EP | claimed |
| US-9102674-B2 | Substituted naphthyridine and quinoline compounds as MAO inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-08-11 | — | — | US | claimed |
| US-20140315944-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE LLC | 2014-10-23 | — | — | US | claimed |
| WO-2014158916-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2014-10-02 | — | — | WO | claimed |
| EP-2970125-B1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2018-07-18 | — | — | EP | disclosed |
| EP-2970125-B1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2018-07-18 | — | — | EP | disclosed |
| US-9956213-B2 | Substituted naphthyridine and quinoline compounds as MAO inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-05-01 | — | — | US | disclosed |
| US-9956213-B2 | Substituted naphthyridine and quinoline compounds as MAO inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-05-01 | — | — | US | disclosed |
| US-9956213-B2 | Substituted naphthyridine and quinoline compounds as MAO inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-05-01 | — | — | US | disclosed |
| US-20170312263-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE LLC | 2017-11-02 | — | — | US | disclosed |
| US-20140315944-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE LLC | 2014-10-23 | — | — | US | disclosed |
| US-20140315944-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE LLC | 2014-10-23 | — | — | US | disclosed |
| WO-2014158916-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014158916-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275548-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE LLC | 2014-09-18 | — | — | US | disclosed |
| US-20140275548-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE LLC | 2014-09-18 | — | — | US | disclosed |
| US-20140275548-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE LLC | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160074377-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | MAOB, MAOA, PNMT | MAOB 1/4885MEN1 3078/4885HSP90AA1 2147/4885 |
| US-20170312263-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | MAOB, MAOA, PNMT | MAOB 1/4885MEN1 3055/4885HSP90AA1 2119/4885 |
| US-20140275548-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | MAOB, MAOA, PNMT | MAOB 1/4885MEN1 3078/4885HSP90AA1 2147/4885 |
| US-20140315944-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | MAOB, MAOA, PNMT | MAOB 1/4885MEN1 3055/4885HSP90AA1 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.